Experts in Pharma Extensions (SPCs & PTEs) and Regulatory Exclusivity

Mewburn Ellis has unparalleled experience with SPCs and other Patent Term Extensions (PTEs). We handled the UK’s first SPC application for leuprorelin back in 1993 and we’ve been in the top three firms for SPC filings in recent years, supporting some of the biggest multinational pharma firms worldwide.

Our Speciality Pharma Team regularly supports large and small clients with their extensions strategies and filings. Before filing SPC applications for a medicinal product there should often be a phase of careful strategic analysis to inform the final key decisions about which patent to extend in each country. To conduct this assessment properly, there often needs to be a detailed appreciation of the regulatory picture surrounding a given drug product, and how it might evolve in the future, to be sure of reaching the right decisions. Specialist understanding is important at this stage to avoid missing critical details and going down the wrong path on such a commercially important decision.

Our Speciality Pharma team includes experienced IP counsel who previously specialised in this area while working in-house for a global pharmaceutical company and our team regularly supports clients with such analysis, before progressing to the SPC and PTE filings themselves.

In other situations, our team has assisted with evaluations and due diligences, to understand the likely timelines of exclusivity around a medicinal product in key countries towards a commercial assessment of the asset.

We encourage pharma and life science companies to work with us from an early stage in order that significant opportunities are not missed in maximising extensions and the overall value of a new medicinal product.

Mewburn Ellis have been involved with key aspects of over 1000 SPCs/PTEs for our clients and we’re well-placed to support you in this specialist area of great commercial importance.

Read our Supplementary Protection Certificates (SPCs) & Patent Term Extensions (PTEs) law and practice guide.

Read more about our expertise in the Pharma & Biologics and Speciality Pharma fields.

Latest News & Insights

Iberdomide's FDA approval: a milestone for molecular glues, CELMoDs and targeted protein degradation

Iberdomide's FDA approval: a milestone for molecular glues, CELMoDs and targeted protein degradation

by Annabel Cardno

Over the last few years, targeted protein degradation (TPD) has evolved into one of the most active fields of drug discovery and biotechnology. Much of the recent attention has focused on emerging ...

Julie Carlisle in Parola Analytics — How are new therapeutic modalities reshaping drug discovery?

Julie Carlisle in Parola Analytics — How are new therapeutic modalities reshaping drug discovery?

by Julie Carlisle

Featured in Parola Analytics, Julie Carlisle explores how new therapeutic modalities are reshaping drug discovery.

Beyond PROTACs and molecular glues: where next for heterobifunctional drug discovery?

Beyond PROTACs and molecular glues: where next for heterobifunctional drug discovery?

by Annabel Cardno

A broader heterobifunctional tool emerges Targeted protein degradation has rapidly progressed from a conceptual curiosity to one of the most closely watched areas in drug discovery. As discussed in ...

General Court confirms Glaxo Inhaler 3D mark is invalid

General Court confirms Glaxo Inhaler 3D mark is invalid

by Rebecca Anderson-Smith

In July 2025, the European Union General Court rejected an appeal against an earlier decision of the Board of Appeal (reported on in our previous article Cipla Europe NV v Glaxo Group Ltd: can a 3D ...

Molecular Glue Degraders (MGDs): what they are, how they work and key IP Issues

Molecular Glue Degraders (MGDs): what they are, how they work and key IP Issues

by Tim Nash

Molecular glue degraders (MGDs) are small molecules that induce or stabilise protein–protein interactions, often by recruiting an E3 ligase to a target protein and triggering its ubiquitination and ...

Orforglipron FDA Approval: Why the First Small-Molecule GLP-1 Pill Matters

Orforglipron FDA Approval: Why the First Small-Molecule GLP-1 Pill Matters

by Andrew Pitts

The GLP-1 landscape changed on 1 April 2026, when the FDA approved Eli Lilly's orforglipron under the brand name Foundayo as the first non-peptide, small-molecule GLP-1 receptor agonist (GLP-1RA) ...

SPC Report Mock-Up v2-compressed

Special Report

Pharma and Life Sciences Patent Extensions in Europe

Having compiled and analysed real-world data, this Special Report sets out to provide valuable insights into the following questions that may face decision-makers handling SPC protection for a new drug:

  1. What do the headline SPC statistics tell us?
  2. How to approach the decision of which patent to extend?
  3. What forms of medical technology are being protected by SPCs?
  4. What SPC periods are typically obtained?
  5. How do SPC periods vary with technology type?
  6. How do SPC periods overlay with regulatory protection?
  7. What commercial value can arise from SPCs?